Heart Failure

Presented at ESC 2023, the accumulation of inactive time from childhood through young adulthood was related to heart damage, regardless of body weight and blood pressure.

A new analysis suggests improved self-recognition of myocardial infarction symptoms may reduce cardiogenic shock and death by prompting a rapid hospital visit.

A multi-center study in France found recreational drug use was independently associated with the occurrence of in-hospital outcomes.

In this episode of Don't Miss a Beat, hosts offer a breakdown of 3 trials of note from the upcoming ESC Congress 2023 and provide context around the recent announcement of topline results from the SELECT trial.

A posthoc analysis of the pivotal SOLOIST-WHF trial provides insight into the effects of sotagliflozin use on risk of cardiovascular mortality and heart failure readmissions at 90 days.

Last week, the FDA authorized marketing for Viz.AI’s Viz HCM, a standalone ECG analysis software to identify adult patients for further follow-up for hypertrophic cardiomyopathy.

The July 2023 cardiology month in review features a Class I recall from the FDA, the latest recommendation statement from the USPSTF, and an update on 3 agents in the pipeline.

Drs James Januzzi, Javed Butler, Robert Mentz, and Muthiah Vaduganathan share practice pearls for treating patients with heart failure, focusing on the future of treatment.

Robert Mentz, MD, reviews the results of the STONG-HF trial for patients in the hospital for heart failure.

Anuradha Lala-Trindade, MD, shares developments in the pipeline for heart failure therapy, as well as clinical pearls for health care providers managing patients with heart failure.

Anuradha Lala-Trindade, MD, discusses the PARAGLIDE-HF trials, highlighting the use of sacubitril/valsartan for the management of heart failure in certain populations.

Data from a phase 1, first-in-human trial of NI006 suggests the agent could have a potential role in the management of transthyretin amyloid cardiomyopathy.

Days with a combination of a heat wave and high fine particulate matter air pollution may double the risk of a fatal heart attack, says new research.

A new analysis suggests Black patients with NICM and an ICD had a high risk and burden of arrhythmia, with a lower survival rate, compared with White patients.

A new analysis from the American Heart Association found present-day heart failure risk was higher among Black adults who lived in areas historically impacted by redlining.

Physical activity concentrated within a 1- to 2-day span was associated with a similarly lower risk of cardiovascular outcomes to more evenly distributed activity.

Anuradha Lala-Trindade, MD, comments on the prevalence of the various types of heart failure, as well as risk factors leading to the disorder.

Anuradha Lala-Trindade, MD, discusses the challenges in managing heart failure in the United States as well as the universal definition of heart failure and classification by left ventricle ejection fraction (EF).

Drs James Januzzi, Javed Butler, Robert J. Mentz, and Muthiah Vaduganathan share approaches to sequencing quadruple therapy in heart failure to the individual patient, as well as optimizing therapy early in the hospitalization stage.

Javed Butler, MD, MPH, MBA, discussesSGLT-2 inhibitors and their use in heart failure.

Experts in cardiology highlight the four pillars of guideline directed therapies in heart failure.

Robert J. Mentz, MD, and James Januzzi, MD, discuss the key takeaways from updated heart failure guidelines, highlighting heart failure stages A and B.

A meta-analysis of 13 trials suggests SGLT2 inhibitors reduced heart failure events and cardiovascular death across these patient populations, with consistent effects in patients with varying disease combinations.

Muthiah Vaduganathan, MD, MPH, and Javed Butler, MD, MPH, MBA, share approaches to treating patients with heart failure, focusing on patient education as well as social determinants of health.

Experts in cardiology review the classification of heart failure using left ventricle ejection fraction (EF).